Whitehawk Therapeutics
WHWK
68 hedge funds and large institutions have $212M invested in Whitehawk Therapeutics in 2022 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 26 increasing their positions, 18 reducing their positions, and 11 closing their positions.
44% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 18
33% more capital invested
Capital invested by funds: $159M → $212M (+$52.9M)
8.48% more ownership
Funds ownership: 63.21% → 71.69% (+8.5%)
0% more funds holding
Funds holding: 68 → 68 (0)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$13.4M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$13M |
| 3 |
AIM
Alerce Investment Management
Chicago,
Illinois
|
+$12.1M |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$4.21M |
| 5 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$2.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
-$14.5M |
| 2 |
State Street
Boston,
Massachusetts
|
-$3.75M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
-$1.27M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.22M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$727K |
WHWK Hedge Fund Activity: Q3 2022 in Review
68 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Whitehawk Therapeutics (WHWK) for Q3 2022, worth a combined $212M — up 33% from $159M a quarter earlier.
Fund positioning in WHWK was balanced in Q3 2022: 11 funds opened new positions, 11 closed out, 26 added to existing stakes and 18 trimmed.
The largest buyer was Avoro Capital Advisors, adding an estimated $13.4M. The largest seller was VR Adviser, exiting entirely with an estimated $14.5M sold.
- 68 institutional investors held Whitehawk Therapeutics (WHWK) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $212M of Whitehawk Therapeutics stock for Q3 2022, up 33% quarter-over-quarter.
- 11 funds opened new Whitehawk Therapeutics positions in Q3 2022 and 11 closed out, a net change of 0 holders.
- The largest Whitehawk Therapeutics buyer in Q3 2022 was Avoro Capital Advisors, an estimated $13.4M added.
- The largest Whitehawk Therapeutics seller in Q3 2022 was VR Adviser, an estimated $14.5M sold.
Based on aggregated 13F filings for Q3 2022.